Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Brexanolone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lipocine Reports Topline Results for LPCN 1154 in PPD Patients
    Lipocine Reports Topline Results for LPCN 1154 in PPD Patients

    02 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lipocine-reports-topline-safety-and-efficacy-results-for-lpcn-1154-in-patients-with-postpartum-depression-302732160.html

    PR NEWSWIRE
    02 Apr 2026
    Share Share
    Lipocine Completes LPCN 1154 Phase 3 Trial Enrollment
    Lipocine Completes LPCN 1154 Phase 3 Trial Enrollment

    20 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lipocine-announces-completion-of-enrollment-and-dosing-in-phase-3-trial-of-lpcn-1154-in-postpartum-depression-ppd-302664877.html

    PR NEWSWIRE
    20 Jan 2026
    Share Share
    Lipocine Advances LPCN 1154 In Postpartum Depression Ph3 Trial
    Lipocine Advances LPCN 1154 In Postpartum Depression Ph3 Trial

    12 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lipocine-reports-encouraging-progress-post-second-interim-safety-review-in-phase-3-trial-of-lpcn-1154-in-postpartum-depression-ppd-302657662.html

    PR NEWSWIRE
    12 Jan 2026
    Share Share
    Lipocine's LPCN 1154 Phase 3 Study Reaches 80% Enrollment
    Lipocine's LPCN 1154 Phase 3 Study Reaches 80% Enrollment

    16 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lipocines-ppd-phase-3-study-lpcn-1154-hits-80-enrollment-milestone-302642892.html

    PR NEWSWIRE
    16 Dec 2025
    Share Share
    Lipocine Showcases LPCN 1154 Phase 3 Trial Safety In Postpartum
    Lipocine Showcases LPCN 1154 Phase 3 Trial Safety In Postpartum

    18 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lipocine-highlights-promising-interim-safety-profile-in-phase-3-trial-of-lpcn-1154-in-postpartum-depression-ppd-302617859.html

    PR NEWSWIRE
    18 Nov 2025
    Share Share
    Lipocine Announces Regulatory Pathway on Oral LPCN 1154 for PPD
    Lipocine Announces Regulatory Pathway on Oral LPCN 1154 for PPD

    15 Sep 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/lipocine-announces-favorable-regulatory-pathway-on-oral-lpcn-1154-for-post-partum-depression-ppd-301624932.html

    PRNEWSWIRE
    15 Sep 2022
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.